A Phase 1 Study of LY3076226, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody-Drug Conjugate, in Patients With Advanced or Metastatic Cancer
Phase of Trial: Phase I
Latest Information Update: 02 Jun 2017
At a glance
- Drugs LY 3076226 (Primary)
- Indications Bladder cancer
- Focus Adverse reactions
- Sponsors Eli Lilly
- 25 May 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Sep 2018.
- 11 Apr 2017 Planned number of patients changed from 65 to 37.
- 08 Oct 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov record.